2025 Speakers:

GLP-1 Peptide Gold Rush: What’s Driving 80% of CDMO Growth

ChemOutsourcing’s GLP-1 panel brought together leading voices from across the outsourcing ecosystem to unpack the forces behind one of pharma’s most explosive growth segments. Representing every corner of the peptide supply chain, Mamun Ayyub (CordenPharma), Tricia Shah (PolyPeptide Group), Steve Beagle (FarmEagle Partners), and Tim Miley(Jitsan Pharma) discussed how obesity drugs have reshaped CDMO capacity, supply chains, and investment strategy almost overnight.

---

From Diabetes to a Global Phenomenon

The conversation opened with Ayyub pointing to the simple catalyst: results. “Obesity is driving roughly 70 percent of GLP-1 revenue,” he said, “and diabetes the other 30.” The class’s success stems from meaningful weight-loss efficacy paired with patient-friendly delivery—weekly injections instead of daily doses—and chemical modifications that extend half-life through albumin binding.

Shah added that the field is quickly broadening beyond metabolic disorders, noting emerging studies in cardiovascular disease, NASH, and even Alzheimer’s. “We’re seeing GLP-1 analogs and related peptides—amylins, GIPs, glucagons—pushed into new indications. That diversity of application keeps the momentum going.”

Beagle offered a blunt snapshot of what that means for manufacturing: “About half of all CDMO expansion right now ties back to GLP-1-type compounds.” The surge, he warned, has created both unprecedented opportunity and looming risk. “It feels like the injectable boom of the early 2000s—great while it lasts, but it will correct. The question is who’s prepared when the wave settles.”

---

Supply Chain Pressure and Tariff Reality

As the discussion turned to supply chain realities, Ayyub highlighted tariffs and raw-material sourcing as key pressure points. Many companies, he said, invested heavily in new capacity before recent trade shifts. A 30 percent tariff on raw materials representing roughly 30 percent of an API’s cost equates to nearly a 10 percent hit to cost of goods—but producing domestically can still be more expensive than importing.

The likely outcome, he suggested, is a regionalization strategy in which APIs are manufactured closer to end markets rather than fully on- or off-shored. Shah echoed that view, adding that the surge has strained amino-acid and linker supply. “Capacity for peptide building blocks must now be planned years ahead,” she said.

---

The Next Frontier: Sustainable Manufacturing

The panel agreed that sustainability and process intensity are fast becoming the next competitive frontier. Ayyub described CordenPharma’s push toward tag-assisted peptide synthesis, which can reduce raw-material use by 40–50 percent and solvent consumption by over 90 percent while improving purity and yield. “You grow sales and still cut your carbon footprint—that’s the new benchmark,” he noted.

Shah pointed to similar efforts across Europe under tightening environmental frameworks, where greener reagents and flow-based methods borrowed from small-molecule chemistry are beginning to define modern peptide manufacturing. These advances, she said, aren’t just about compliance—they’re becoming major differentiators in CDMO selection.

---

Competing on Speed, Reliability, and Trust

Miley emphasized that for clients, reliability and speed outweigh everything else. “Quality is expected—it’s the price of entry,” he said. “The differentiator is how fast you can quote, qualify, and deliver without sacrificing compliance.” He credited China’s peptide sector with unmatched turnaround time and technical capability, though all agreed geopolitical uncertainty demands diversified sourcing.

Despite warnings of overcapacity, Beagle closed on a note of cautious optimism. Oral and longer-interval delivery formats are emerging, combination agonists are reducing API requirements per patient, and innovation continues at a breakneck pace. “The GLP-1 market won’t vanish,” he said, “it will evolve—and the CDMOs that adapt their chemistry, sustainability, and supply strategies fastest will own the next chapter.”

---

The Takeaway

The GLP-1 boom has redefined what growth looks like for contract manufacturers. As peptides move into new indications and delivery formats, success will hinge less on volume and more on efficiency, adaptability, and sustainability. The panel agreed: the gold rush isn’t about chasing demand—it’s about building the resilient, high-speed, and low-impact manufacturing models that will outlast it.